Publications by authors named "Molly Geare"
Clin Cancer Res
November 2021
Article Synopsis
- The study evaluates the combination of the histone deacetylase inhibitor entinostat with immune checkpoint inhibitors (ICIs) nivolumab and ipilimumab in patients with advanced solid tumors, aiming to enhance treatment efficacy.
- Thirty-three patients participated in the trial, experiencing treatment-related side effects like fatigue and anemia, while the recommended phase II dosing was determined to be 3 mg of entinostat weekly, along with specified doses of nivolumab and ipilimumab.
- Results showed a 16% objective response rate, including a complete response in a case of triple-negative breast cancer, and a significant increase in CD8 effector to FoxP3 regulatory T cell ratios, highlighting the
